Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients.
about
Roles of HTLV-1 basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related DiseasesRecent Advances in BLV ResearchModes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and PersistenceBlood-brain barrier and retroviral infectionsRates of CTL killing in persistent viral infection in vivoIs human T cell lymphotropic type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) syndrome a neglected disease?Newly emerging therapies targeting viral-related lymphomas.Chemoresistance to Valproate Treatment of Bovine Leukemia Virus-Infected Sheep; Identification of Improved HDAC Inhibitors.Massive depletion of bovine leukemia virus proviral clones located in genomic transcriptionally active sites during primary infection.Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid.Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy.Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/TrHTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.Targeting histone deacetylases for the treatment of diseaseCD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.A Fashi Lymphoproliferative Phenotype Reveals Non-Apoptotic Fas Signaling in HTLV-1-Associated NeuroinflammationInflammatory manifestations of HTLV-1 and their therapeutic options.HIV-1 Vpr Protein Induces Proteasomal Degradation of Chromatin-associated Class I HDACs to Overcome Latent Infection of Macrophages.Downregulation of histone methyltransferase EHMT2 in CD4(+) T-cells may protect HTLV-1-infected individuals against HAM/TSP development.Antiviral effect of raltegravir on HTLV-1 carriers.Inhibition of enveloped virus infection of cultured cells by valproic acid.Molecular and Cellular Mechanism of Leukemogenesis of ATL: Emergent Evidence of a Significant Role for HBZ in HTLV-1-Induced Pathogenesis.Conference highlights of the 16th International Conference on Human Retrovirology: HTLV and related retroviruses, 26-30 June 2013, Montreal, Canada.Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant.HTLV-1-associated myelopathy/tropical spastic paraparesis.How Does HTLV-1 Undergo Oncogene-Dependent Replication Despite a Strong Immune Response?HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment.HTLV-1: Regulating the Balance Between Proviral Latency and Reactivation.How to Control HTLV-1-Associated Diseases: Preventing de Novo Cellular Infection Using Antiviral Therapy.[HTLV-1-associated myelopathy/tropical spastic paraparesis: a differential diagnosis in multiple sclerosis].[Virological aspects of HTLV-1 infection and new therapeutical concepts].
P2860
Q26774352-E84A816B-A28C-4D70-9C46-B9C11A85C3C0Q26776531-43E3EEA8-FDD8-417F-8A71-D43567C3BF28Q26801294-689B0891-AC0E-436F-B0A7-F631E23EF2D6Q26830903-E3C61F4D-8EE6-4CED-864E-0513C4DD8E9EQ27322823-B2FECBD4-47F3-49C3-88D7-EC55FB09E3FDQ30913837-FB1C17E6-6B43-4E4B-A719-4C3AD509A23FQ33699201-B885866D-367D-4E4C-9705-92E86C9A8645Q34533413-F21C9D31-F2E3-489A-8870-77359329B8F9Q35008829-C4324FB3-5177-4A2D-9839-BB9D4E5CA40BQ35261563-DB3B1B8E-0EF3-459C-8C9E-E10532DE00CFQ35833900-DD569B70-8B01-435A-982A-0132FC0DD08AQ36147455-71352E94-7C17-4DEE-A689-08DE68C08287Q36157642-82582886-664A-497D-BDD0-4EA4E92EE24CQ37079191-E5C2D84E-8E5D-48A7-8F93-7BD5EF2E40CDQ37296159-42654512-E016-4638-8A37-121E992C90B5Q37579811-F13C0DFF-3868-4D6E-827B-62F456002C4DQ37639788-3CAE8434-9C06-4AFC-BF4F-359A4F83F104Q38262169-04F05256-7F1F-4B7C-B3BF-26D853A8EBE6Q38265455-52B57C71-EA22-49E3-A568-38191A271B0CQ38950117-2FACB2A2-2321-46F7-89A7-C6E0EDE906A7Q39533380-D0B2D880-B8D0-4C32-B60B-BD2FCB6A2749Q39813573-7FB680CB-6588-49D6-97C6-9C4D568C32A6Q41724491-9AA2FBD1-CD49-4D17-B7DF-E694FEFED879Q42426735-C929F43A-91C8-443D-B1C1-C626233E9824Q44745178-52DE822D-20C0-4E16-A4F6-EB65E89FEA47Q45096240-47EC5B56-D4D8-4244-A0FE-484452C89697Q47548079-5F58EF7D-F1AB-4F40-BB68-A38C68805C9AQ47562043-C41877F2-78C5-4767-AA7D-0C8F1BFD929DQ52721841-61013828-3E28-4AC1-83C0-B7D7988A0619Q54246489-CFFB9709-8F13-4FC9-9B01-A19FB9E67A81Q55239219-1D662F89-B327-4699-84B9-51B4656FBDDAQ55239254-E547E918-12BB-49F3-80DC-85B3A09DF805
P2860
Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Histone deacetylase mediated t ...... spastic paraparesis patients.
@en
Histone deacetylase mediated t ...... spastic paraparesis patients.
@nl
type
label
Histone deacetylase mediated t ...... spastic paraparesis patients.
@en
Histone deacetylase mediated t ...... spastic paraparesis patients.
@nl
prefLabel
Histone deacetylase mediated t ...... spastic paraparesis patients.
@en
Histone deacetylase mediated t ...... spastic paraparesis patients.
@nl
P2093
P50
P1433
P1476
Histone deacetylase mediated t ...... spastic paraparesis patients.
@en
P2093
Agnès Lezin
Aïssatou Signaté
Didier Smadja
Gildas Belrose
John Hiscott
Luc Willems
Nathalie Grandvaux
Olivier Verlaeten
Stéphane Olindo
P304
P356
10.1182/BLOOD-2007-04-085076
P407
P577
2007-08-23T00:00:00Z